trial
as of 2026-07-01A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
NCTId NCT04158687
at a glance
Phase 2 · Completed
Enrollment 326 (actual)
Sponsored by Concert Pharmaceuticals
Primary completion 2020-12-22
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
326 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-11-26
Primary completion
2020-12-22
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Drugs
Indications
Sponsors
Concert PharmaceuticalsLead Sponsor
Cognitive Research CorporationCollaborator
Sites
26 total
Little Rock, United StatesRogers, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesOakland, United StatesTorrance, United StatesLauderhill, United StatesNorth Miami, United StatesAtlanta, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
326
Phase
PHASE2
Primary Completion Date
2020-12-22
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
indication
indication
indication